UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOTRICITY INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 3845 (Primary Standard Industrial Classification Code Number) 30-0983531 (I.R.S. Employer Identification Number) 203 Redwood Shores Parkway, Suite 600 Redwood City, CA 94065 (904) 496-0027 (Address, including zip code, and telephone n ...

Financial Data and Key Metrics Changes - For the second quarter of fiscal 2026, revenue increased by 19% to $3.9 million from $3.3 million in the prior year period, reflecting strong market adoption and strategic initiatives [9] - Gross profit for the quarter totaled $3.2 million, up 29.4% from $2.5 million in the prior year period, with a gross profit percentage improvement of 660 basis points to 81.9% [9][10] - The company achieved EBITDA of $373,000 this quarter, marking the second consecutive quarter of positive EBITDA, indicating progress towards profitability [12] Business Line Data and Key Metrics Changes - Technology fees accounted for 89% of the quarter's total revenue, highlighting strong customer satisfaction and retention [9] - The next-generation cardiac monitoring device, Biocorp Pro, has seen expanded sales, contributing to the company's revenue growth and market presence [4][5] Market Data and Key Metrics Changes - Biotricity has monitored over 2 trillion heartbeats, significantly improving patient outcomes for those with atrial fibrillation, which is a primary focus for the company [8] - The company is expanding its market reach through strategic partnerships, including contracts with the VA and leading home care groups [5] Company Strategy and Development Direction - The company is focused on innovation and operational efficiency, aiming to achieve economies of scale and maintain healthy net margins similar to SaaS-like businesses [3] - Future plans include expanding the commercial team and investing profits into commercial expansion to increase market share and drive top-line growth [5][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability in the next few quarters, supported by positive cash flows and improved operating results [12][13] - The growing market interest in chronic cardiac disease management reinforces the company's confidence in its market position and future growth [14] Other Important Information - Operating expenses for the second quarter were $2.9 million, a slight increase from $2.8 million in the same period last year, with strategic investments in R&D and sales force efficiency [11] - The net loss attributable to common shareholders for the quarter was $772,000, a significant reduction from $1.6 million in the prior year period [13] Q&A Session Summary - There were no questions during the Q&A session, indicating a clear communication of the company's progress and future plans [16]